Ingrid Mayer
Faculty Member
Last active: 3/23/2014

Breast cancer, version 3.2013: featured updates to the NCCN guidelines.

Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, National Comprehensive Cancer Network
J Natl Compr Canc Netw. 2013 11 (7): 753-60; quiz 761

PMID: 23847214 · PMCID: PMC3991132 · DOI:10.6004/jnccn.2013.0098

These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer.

MeSH Terms (8)

Breast Neoplasms Female Humans Molecular Targeted Therapy Neoplasm Metastasis Neoplasm Staging Receptor, ErbB-2 Recurrence

Connections (1)

This publication is referenced by other Labnodes entities: